Immunoregulation of Murine Myeloma Cell Growth and Differentiation; A Monoclonal Model of B Cell Differentiation<sup>1</sup>

Lynch, Richard G.; Rohrer, James W.; Odermatt, Bernhard; Gebel, Howard M.; Autry, Johnna R.; Hoover, R G

doi:10.1111/j.1600-065x.1979.tb00298.x

Cited by 135 publications

(40 citation statements)

References 46 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the murine model we observed that IgA myelomiia was accompaniied by increased numlilbers of Ta cells (7) (17). If FcR+ T cells \,ere found to influence myelomacl cells they might offer a new therapeuitic strategy for the cliniecal manipulation of myelomia.…”

Section: Resultsmentioning

confidence: 84%

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Hoover¹,

Hickman²,

Gebel³

et al. 1981

J. Clin. Invest.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 84%

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Hoover¹,

Hickman²,

Gebel³

et al. 1981

J. Clin. Invest.

View full text Add to dashboard Cite

“…One such example is a mineral oil-induced plasmacytoma in BALB͞c mice-designated MOPC-315 (12)-that has been used for the study of the clinical and immunological aspects of human myeloma (13)(14)(15). Similar to the human myeloma cells, the in vivo passaged MOPC-315 tumor cells synthesize and secrete a monoclonal Ig (IgA 2 ), thereby providing a measurable marker of tumor load (serum protein component) during tumor progression.…”

mentioning

confidence: 99%

Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

Mittelman

Neumann²,

Peled³

et al. 2001

Proc. Natl. Acad. Sci. U.S.A.

149

118

View full text Add to dashboard Cite

Recombinant human erythropoietin (rHuEpo) has been used successfully in the treatment of cancer-related anemia. Clinical observations with several patients with multiple-myeloma treated with rHuEpo has shown, in addition to the improved quality of life, a longer survival than expected, considering the poor prognostic features of these patients. Based on these observations, we evaluated the potential biological effects of rHuEpo on the course of tumor progression by using murine myeloma models (MOPC-315-IgA 2 and 5T33 MM-IgG 2b). Here we report that daily treatment of MOPC-315 tumorbearing mice with rHuEpo for several weeks induced complete tumor regression in 30 -60% of mice. All regressors that were rechallenged with tumor cells rejected tumor growth, and this resistance was tumor specific. The Epo-triggered therapeutic effect was shown to be attributed to a T cell-mediated mechanism. Serum Ig analysis indicated a reduction in MOPC-315 light chain in regressor mice. Intradermal inoculation of 5T33 MM tumor cells followed by Epo treatment induced tumor regression in 60% of mice. The common clinical manifestation of myeloma bone disease in patients with multiple-myeloma was established in these myeloma models. Epo administration to these tumor-bearing mice markedly prolonged their survival and reduced mortality. Therefore, erythropoietin seems to act as an antitumor therapeutic agent in addition to its red blood cell-stimulating activity.

show abstract

“…In murine myeloma models, T cells ated in longitudinal studies. In addition, we have demonwith a specificity for these antigens have been detected [1][2][3] and strated that the presence of idiotype-reactive T cells correlates an antitumour response involving both T cell cytotoxicity and with the presence of rearrangements in the T cell receptor ␤ protective immunity has been demonstrated. This response gene.…”

mentioning

confidence: 99%

The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma

Yuen

Nelson

et al. 1997

Leukemia

View full text Add to dashboard Cite

Clonal T cell populations with idiotype specificity are present to CD3 stimulation which boosts antitumour effector mechin the peripheral blood of a proportion of patients with multiple anisms. 15 It has also been shown that increased numbers of myeloma. We have identified the presence of both T cell subactivated suppressor T cells or NK cells are a good prognostic populations with a specificity for autologous immunoglobin factor at diagnosis. 16,17 fragments and T cell receptor ␤ gene rearrangements in periph-The presence of T cell receptor ␤ gene rearrangements has vations provide evidence for the existence of idiotype-reactive

show abstract

Immunoregulation of Murine Myeloma Cell Growth and Differentiation; A Monoclonal Model of B Cell Differentiation¹

Cited by 135 publications

References 46 publications

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma

Contact Info

Product

Resources

About

Immunoregulation of Murine Myeloma Cell Growth and Differentiation; A Monoclonal Model of B Cell Differentiation1

Cited by 135 publications

References 46 publications

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.

Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma

Contact Info

Product

Resources

About

Immunoregulation of Murine Myeloma Cell Growth and Differentiation; A Monoclonal Model of B Cell Differentiation¹